Anzeige
Mehr »
Montag, 02.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHDZ | ISIN: AU0000043945 | Ticker-Symbol: PBN
Frankfurt
02.03.26 | 08:11
0,002 Euro
-60,00 % -0,003
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0020,00815:29

Aktuelle News zur ALTERITY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:30ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments2
ALTERITY THERAPEUTICS Aktie jetzt für 0€ handeln
DoALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
MiALTERITY THERAPEUTICS LIMITED: Half Yearly Report and Accounts1
30.01.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
30.01.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update130- Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced - Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and...
► Artikel lesen
30.01.ALTERITY THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report3
21.01.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026210MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing...
► Artikel lesen
21.01.ALTERITY THERAPEUTICS LIMITED: ATH Shareholder Letter January 20261
15.01.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
15.01.ALTERITY THERAPEUTICS LIMITED: Notification regarding unquoted securities - ATH3
15.01.ALTERITY THERAPEUTICS LIMITED: Notification regarding unquoted securities - ATH2
13.01.ALTERITY THERAPEUTICS LIMITED: Corporate Presentation1
07.01.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
07.01.ALTERITY THERAPEUTICS LIMITED: Change of Director's Interest Notice - D Stamler-
07.01.ALTERITY THERAPEUTICS LIMITED: Notification of cessation of securities - ATH1
24.11.25ALTERITY THERAPEUTICS LIMITED: Initial Director's Interest Notice - Barbaczy3
24.11.25ALTERITY THERAPEUTICS LIMITED: Initial Director's Interest Notice - Stamler-
24.11.25ALTERITY THERAPEUTICS LIMITED: Final Director's Interest Notice - Meltzer2
24.11.25ALTERITY THERAPEUTICS LIMITED: Final Director's Interest Notice - Kempler2
21.11.25ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1